Bioheart, Inc.

Bioheart, Inc., a biotechnology company, focuses on discovering, developing, and commercializing autologous cell therapies for the treatment of chronic and acute heart damage. Its lead product candidate is MyoCell, a clinical therapy designed to populate regions of scar tissue in a patient’s heart with autologous muscle cells, or cells from the patient’s body for improving cardiac function in chronic heart failure patients. The company’s products under development include Bioheart Acute Cell Therapy, an autologous adipose cell treatment for the treatment of acute heart damage; TGI 1200 Adipose Tissue Processing System, an automated device for the rapid processing of patient derived fat tissue; and MyoCell SDF-1, an autologous cell therapy for the treatment of severe chronic damage to the heart and cells modified to express angiogenic factors. Its products candidates also include MyoCath, a disposable endoventricular catheter for the delivery of biologic solutions to the myocardium; BioPace for the treatment of chronic abnormal heart rhythm; AlloCell, an allogenic cell-therapy treatment for severe chronic damage to the heart; and MyoCath II, a second generation disposable endoventricular catheter to provide multidirectional cell injection for the delivery of biologic solutions to the myocardium. Bioheart, Inc. was founded in 1999 and is headquartered in Sunrise, Florida.